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Abstract 
Backgound  The influence of gender on clinical outcomes following transcatheter aortic valve implantation (TAVI) was considerably 
discrepant in previous studies. We aimed to investigate the impact of gender in our registry. Methods  The study is a retrospective observa-
tional analysis of a prospectively designed cohort (546 consecutive patients treated at the University Hospital Zurich who were enrolled in 
Swiss TAVI Cohort from May 2008 to April 2014). The Study took place in University Heart Centre at University Hospital Zurich, Switzer-
land. Results  Both genders were equally represented with 51.5 % (n = 281) of the populations being females, who were significantly older 
and had a more pronounced history of hypertension (P < 0.001). Males on the other hand showed a higher incidence of diabetes (P = 0.004), 
coronary artery disease (P < 0.001), chronic obstructive pulmonary disease (P < 0.001) and renal failure requiring renal replacement therapy 
(P = 0.018). Patients were followed up for a median of 391 days with a 100% complete follow-up at one year. The primary outcome 
(all-cause mortality) occurred in 6.8% (n = 37) and 15% (n = 82) of patients at 30 days and one year, respectively. The 30-day all-cause mor-
tality outcome did not significantly differ between females (7.5%) and males (6.0%) (P = 0.619), but one year all-cause mortality occurred 
significantly more in males than in females (18.7% vs. 11.7%, P < 0.037). Conclusion  After TAVI implantation for severe aortic stenosis, 
males have a less favorable long-term (one year) mortality outcome than females. 
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1  Introduction 
Aortic stenosis is the most common valvular heart dis-
ease in the elderly, and a considerable increase in its inci-
dence is foreseen for the coming decades because of the 
progressive aging of western populations.[1,2] Importantly, 
symptomatic aortic stenosis is not only associated with 
breathlessness, angina and syncope, but also with a high rate 
of death, if left untreated.[3–5] 
Several studies reported sex-related incidence of compli-
cations and death after TAVI, but their results are inconsis-
tent.[6–10] In 2015, Conrotto and his colleges published a meta- 
analysis, in which they analyzed six studies with 6645 pa-
tients from a MEDLINE search, Cochrane Library and 
Scopus databases and found that female gender was signifi-
cantly related to a lower risk of death with an odds ratio of 
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0.82 at one year, but no Mortality difference at 30 day post 
TAVI.[9] A previous meta-analysis from China that involved 
27 articles with a total of 9118 patients, concluded that male 
gender was associated with significantly higher risk for 
death at both 30 days with a relative risk of 1.37 and at one 
year with a relative risk of 1.30.[8] This was in contrast to the 
retrospective analysis published by the UK National Insti-
tute for Cardiovascular Outcomes Research that investi-
gated 1627 patients from the UK TAVI registry and found 
no gender-related mortality difference at 30 day and one year 
follow up.[10] 
In view of considerable discrepancies with regard to 
gender-related differences in complications and outcomes 
after TAVI and the fact that the contributing factors remain 
incompletely understood; we designed this retrospective 
observational study to explore the prognostic influence of 
gender in patients who underwent TAVI in our registry. 
2  Methods 
2.1  Setting  
The study is a retrospective observational analysis of a 
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prospectively designed cohort (546 consecutive patients 
treated at the University Hospital Zurich who were enrolled 
in Swiss TAVI Cohort from May 2008 to April 2014). The 
Study took place in University Heart Centre at University 
Hospital Zurich, Switzerland. 
2.2  Study population  
All patients have been selected for TAVI after multidis-
ciplinary team review by a dedicated heart team of invasive 
and non-invasive cardiologists, cardiac surgeons and anes-
thesiologists at our institution. Voluntary informed written 
consent was obtained from all patients to be included in the 
Swiss TAVI registry. 
2.3  TAVI procedure 
TAVI was performed via either the transfemoral, trans-
apical or transaortic routes with implantation of diverse 
valves such as the Medtronic’s CoreValve®, Edwards®, 
Symetis® or Ventor Embracer®. A transfemoral first policy 
was applied, if non-applicable due to any reason (i.e., fe-
moral artery size, aortic disease among others) then alternate 
access routes were considered. 
All procedures conducted through transapical and transaor-
tic routes were performed under general anesthesia, whereas 
devices implanted through the transfemoral route were most 
commonly performed with sedation with local anesthesia 
and only rarely under general anesthesia.  
Transthoracic echocardiography was used to measure 
aortic valve pressure gradient and aortic valve area before 
TAVI. Aortic regurgitation grade and left ventricular ejec-
tion fraction (LVEF) before and after TAVI was also deter-
mined in each patient using echocardiography. Mean aortic 
gradient was further confirmed during cardiac catheteriza-
tion with invasive measurement before and after the proce-
dure. The Valve Academic Research Consortium Criteria 
were used to assess and evaluate procedural success, safety 
end points and clinical outcomes.[11] 
2.4  Eligibility 
Inclusion criteria were elderly patients with symptomatic 
severe aortic stenosis, deemed at high risk for conventional 
surgical aortic valve replacement. Exclusion criteria were 
patient’s refusal of informed consent to participate in the 
registry or lack of capacity to consent and/or high proba-
bility of non-adherence to follow-up requirements. 
2.5  Outcomes 
The primary outcome comprised all-cause death at 30 
days and one year. The secondary outcomes were complica-
tions at 30 days after TAVI including stroke, major bleeding, 
major vascular access related complications, deranged crea-
tinine level, and valve related dysfunction; other studied 
outcomes were the occurrence of any of the following dur-
ing the one year follow-up: valve related dysfunction, 
NYHA III or IV, hospitalization for valve related symptoms 
and the requirement for a pacemaker implantation. All 
clinical end points were in concordance with the widely 
accepted VARC-2 definitions. 
2.6  Statistical analysis 
Descriptive statistics were performed using summary sta-
tistics (mean, standard deviation, and range) for quantitative 
variables and frequencies for binary and nominal variables. 
Demographic and clinical variables were tested at baseline 
against the primary variable of interest (gender) using pa-
rametric t test, non-parametric chi-square test, or non-pa-
rametric Wilcoxon rank sum test as appropriate. Box-and- 
whisker plots were used to display such relationships. We 
evaluated the unadjusted effect for gender on survival fol-
lowing TAVI procedure, and then moved on to include the 
potential clinical and demographic covariates utilizing the 
log-likelihood and behaviour of the residuals to assess the 
model fit and confirm the independent impact of gender on 
survival posy-TAVI. Kaplan-Meier plots were used to dis-
play the cumulative survival functions of males and females 
in terms of the prognostic outcomes specified. 
We used the statistical software package SPSS-20 for 
windows to perform the statistical analysis and for pro-
ducing graphs and plots. The statistical significance thresh-
old was set at 5%. 
3  Results 
3.1  Baseline and procedural characteristics 
Male and female participants of the study were com-
parable in numbers (49.5 % vs. 51.5%). With regard to age, 
females tended to be significantly older than males (mean: 
83.3 ± 6.95 vs. 80.7 ± 6.91 years, P < 0.001), while males 
outnumbered females in terms of the following co-mor-
bidities: diabetes mellitus (59.8% vs. 40.2%, P = 0.004 ), 
cardiovascular disease (CAD; 58.7% vs. 41.3%, P < 0.001), 
chronic obstructive airway disease (COPD; 65.0% vs. 
35.0%, P = 0.0003), renal impairment (mean: 130.48 ± 72 
vs. 100.95 ± 71 µmol/L, P < 0.001) and the need for regular 
dialysis (76.2% vs. 23.8%, P = 0.018). On the other hand, 
there were far less hypertensive males than females [46.4% 
vs. 53.6%, respectively (P < 0.001)].  
In terms of pre-procedural left ventricular ejection frac-
tion (LVEF), the mean value averaged 55% (SD = 13.3%, 
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range: 19%88%), with males tending to have significantly 
lower LVEF than females (51.5% ± 13.9% vs. 58.4% ± 
11.7%, P < 0.001). These differences in baseline character-
istics were reflected in a significantly higher logistic Euro-
SCORE of males 22.7% ± 14%) compared to females 
(21.1% ± 12.7%; P = 0.031).  
The common femoral artery was the most common ac-
cess site in 85.2% of the cases. In terms of valve types, both 
the CoreValve® (50.5%) and Edwards® Valve (48.4%), 
were most commonlly used, while only a few patients 
received the Symetis® or Ventor® device (1.2% of the cases). 
With respect to gender differences, more CoreValve® and 
Symetis® were used in females, whereas more Edwards 
Sapien® were used in males, a difference that reached statis-
tically significance (P = 0.003).  
The complete list of baseline characteristics of the pa-
tients is depicted in Table 1. 
3.2  Primary outcome 
3.2.1  30-day mortality 
In terms of the 30-day all-cause mortality, death occurred 
in 6.6% of patients (n = 37), which was not statistically dif-
ferent between females (7.5%; n = 21) and males (6.0%; n = 
16) (X2 = 0.2467, df = 1, P = 0.6194) 
3.2.2  1-year mortality after TAVI 
In terms of the 1-year all-cause mortality following TAVI, 
the overall mortality rate was 15.0% (n = 82), 11.7% (n = 33) 
females vs. 18.4% (n = 49) males. Applying the Cox regres-
sion hazards model, females were more likely to survive > 1 
year following TAVI procedure than males (HR = 1.436, P 
= 0.037); Figures 1 & 2. 
Even after adjusting for the effect of all other covariates, 
the effect of gender on the risk of post-TAVI mortality was 
statistically significant (adjusted HR = 1.71, P = 0.015). So, 
in patients with comparable covariates, a male patient, will 
have an increased risk of death after a TAVI than a female 
patient by 71.0% (95% CI: 11.0%163.6%). 
3.3  Secondary outcomes 
Males tended to have higher creatinine plasma levels 
post-TAVI compared to females (148 ± 101 vs. 109.7 ± 98 
mg/dL, P < 0.001; Figure 3). 
Regarding the other possible gender-related differences 
in outcomes 30 days after TAVI, all were statistically non- 
significant during short term follow-up (i.e., major bleeding, 
vascular complications, stroke, valve dysfunction and fol-
low-up NT brain natriuretic plasma level during hospitaliza-
tion post TAVI) as well as the differences in long-term out-
comes during the entire period of follow-up post TAVI (i.e., 
all causes of valve dysfunction, NYHA III or IV, hospitali-
zation for valve related symptoms or pacemaker implanta-
tion) were also not statistically significant. The complete list of 
the primary and secondary outcomes is depicted in Table 2. 
Table 1.  Baseline characteristics and procedural demographics. 
Variable All patients Males Females P Value 
Age, yrs  82 ± 7.6 80.7 ± 6.91 83.3 ± 6.95 < 0.001 
BMI, kg/m2 26.4 ± 4.6 26.4 ± 4.34 26.3 ± 4.86 0.685 
Diabetes mellitus 132 (24.2%) 79 (59.8%) 53 (40.2%) 0.004 
Dyslipidemia 207 (37.9%) 103 (49.8%) 104 (50.2%) 0.72 
Systemic hypertension 403 (37.9%) 187 (46.4%) 216 (53.6%) < 0.001 
Coronary artery disease 298 (83.8%) 175 (58.7%) 123 (41.3%) < 0.001 
Cerebrovascular accidents 103 (18.9%) 56 (54.4%) 47 (45.6%) 0.228 
Aortic Valvuloplasty 20 (3.7%) 10 (50%) 10 (50%) 1 
Dialysis 21 (3.8%) 16 (76.2%) 5 (23.8%) 0.018 
Peripheral vascular disease 110 (20.2%) 63 (61.2%) 47 (45.6%) 0.052 
COPD 103 (18.9%) 67 (65.0%) 36 (35.0%) < 0.001 
Creatinine, µmol/L 115 ± 72 130.48 ± 72 100.95 ± 71 < 0.001 
B-type natriuretic peptide, pg/mL 4903 5860 4004 0.23 (Log trans = 0.156)
Hemoglobin, mean g/L 98.4 101.9 95.1 0.0883 
LVEF    55% ± 13.3% 51.5% ± 13.9% 58.4% ± 11.7% < 0.001 
Logistic EuroSCORE  21.4% ± 15.1% 22.7% ± 14% 21.1% ± 12.7% 0.031 
EuroSCORE II  7.3% ± 6.1% 7.8% ± 6.9% 6.9% ± 5.2% 0.151 
STS score, mean 6.6 7.1 6.1 0.0533 
Access (n, femoral, apical, aortic) (461, 79, 1) (237, 38, 1) (224, 41, 0) 0.587 
Device (CorValve, Sapien, Symetis, Ventor) (273, 262, 3, 3) (121, 155, 0, 2) (152, 107, 3, 1) < 0.0039 
Data are presented as mean ± SD or n (%) unless other indicated. BMI: body mass index; COPD: chronic obstructive airway disease; LVEF: left ventricular 
ejection fraction. 
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Figure 1.  One year mortality outcome after transcatheter 
aortic valve implantation. 
4  Discussion 
The current study shows a significant survival benefit of 
females undergoing TAVI when compared to male patients 
with severe and symptomatic aortic stenosis. This benefit, 
although not obvious at 30 days, was significant at one year 
follow-up with an odds ratio of 1.70. Our finding therefore 
support the findings of the Italian meta-analysis of 6 studies 
incorporating 6645 patients, where they found that female 
gender was significantly related to a lower risk of death at 
one year, but not at 30 day post TAVI.[9] 
There is currently no clear cut explanation for the fact 
that women do better than men after TAVI. However, the 
 
Figure 2.  Cumulative survival after TAVI. TAVI: transcathe-
ter aortic valve implantation. 
 
Figure 3.  Highest creatinine after transcatheter aortic valve 
implantation. 
Table 2.  Clinical outcomes after TAVI. 
Variable All patients Males Females P value 
One-year all-cause mortality 82 (15%) 49 (18.4%) 33 (11.7%) 0.037 
30-day all cause ortality 37 (6.8%) 16 (6.0%) 21 (7.5%) 0.619 
30-day stroke 21 (3.8%) 13 (4.9%) 8 (2.8%) 0.062 
30-day vascular complications 23 (4.2%) 7 (2.6%) 16 (5.6%) 0.118 
30-day major bleeding 13 (2.4%) 8 (3.0%) 5 (1.8%) 0.447 
30-day valve dysfunction 9 (1.6%) 6 (2.2%) 3 (1.1%) 0.447 
Highest creatinine after TAVI 128.4 ± 100 148.0 ± 101 109.7 ± 98 < 0.001 
BNP after TAVI, pg/mL 6523 7430 5646 0.4012 
All strokes after TAVI 29 (5.3%) 18 (6.8%) 11 (3.9%) 0.13 
NYHA class III or IV after TAVI 55 (11.1%) 28 (10.5%) 27 (9.6%) 0.8 
Hospitalization after TAVI 51 (9.3%) 29 (10.9%) 22 (7.8%) 0.291 
Valve related dysfunction after TAVI 163 (42.6%) 75 (28.3%) 88 (31.3%) 0.499 
Pacemaker Implantation 103 (18.9%) 59 (22.2%) 44 (15.6%) 0.06254 
Data are presented as mean ± SD or n (%) unless other indicated. TAVI: transcatheter aortic valve implantation. 
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interplay of several risk factors and co-morbidities as well 
as different gender-related cardiac pathophysiological re-
sponses to pressure afterload might be involved. Indeed, 
gender has a major impact on the development of left ven-
tricular hypertrophy due to a different response to pressure 
overload.[12–15] Indeed, women with aortic stenosis tend to 
develop a more concentric form of left ventricular hyper-
trophy with smaller ventricular diameters, greater relative 
wall thicknesses, and a better systolic function, while men 
with comparable degree of pressure overload exhibit a more 
eccentric form of left ventricular hypertrophy with more 
ventricular dilation, fibrosis, a decreased ejection fraction 
and development of heart failure.[12,16] In line with this inter-
pretation, males of our cohort were found to have statisti-
cally significant lower left ventricular hypertrophy at the 
time of TAVI compared to females (51.5% vs. 58.4%). This 
finding could as well be explained by the fact that more 
aggressive cardiac remodeling is normally seen in men sec-
ondary to longstanding pressure overload; eventually lead-
ing to a more dilated left ventricle and less favorable ge-
ometry to preserve systolic function.[17,18]  
At the cellular level, there is a large body of evidence 
linking such an abnormal myocardial hypertrophy and fi-
brosis in men with aortic stenosis to increased expression 
of transforming growth factor beta-1 protein (TGF-β1) 
and phosphorylation of SMAD2. Furthermore, periostin, a 
down-stream target of TGF-β1 signaling and a key regulator 
of cardiac fibrosis is more expressed in men.[19] In human 
failing hearts, up-regulation of periostin expression is asso-
ciated with cardiac fibrosis.[20] Higher periostin levels were 
finally found in blood obtained from male compared with 
female patients with heart failure. This link between pattern 
of remodeling and survival raises the question of optimizing 
the management of aortic stenosis in a sex-specific man-
ner.[21–23] 
From a metabolic point of view, recent findings linking 
aortic stenosis to common atherosclerotic pathways could 
help to further explain the lower incidence of coronary ar-
tery disease in females in conjunction to the protective role 
of estrogen with its anti-atheromatous effects, aiding to better 
area of viable myocardium reflected by a higher left ven-
tricular ejection fraction and swift recovery post TAVI in 
females.[24,25] The latter finding of higher left ventricular 
ejection fraction and lower percentage of coronary artery 
disease in women undergoing TAVI compared to men was 
documented in our study as well as in many other studies 
like the UK TAVI registry and other Meta-analyses.[8–10] 
It is also worth noting that males in our cohort were evi-
dently a sicker population than females, as they had an 
overall higher surgical risk reflected by a slightly higher 
Logistic EuroSCORE, along with a higher incidence of co-
morbidities and cardiovascular risk factors including but not 
limited to diabetes mellitus, coronary artery disease and 
renal impairement, in some even requiring hemodialysis. Of 
note, males tend to have significantly higher creatinine 
post-TAVI than females. However, this was also true for 
baseline pre-procedural creatinine levels. Furthermore, in 
logistic regression analysis we found that an increase in 
eGFR by one unit makes a patient, on average, less likely to 
die within 30-days post TAVI (OR = 0.003, 95% CI: 
0.005 to 0.001). This impact of renal function has long 
been addressed in patients undergoing surgical valve re-
placement, where chronic kidney disease and acute kidney 
injury after the procedure were both found to be independ-
ent predictors of mortality.[26–28] However, these variables 
created a bit of controversy regarding their predictive ability 
in TAVI, While some studies have found a staged classifi-
cation of chronic kidney disease before valve implantation 
to be a predictor of both mortality and the development of 
acute kidney injury, others did not share the same view. 
Furthermore, the association of acute kidney injury with 
worse outcome is also still debatable due to similar incon-
sistencies in studies’ outcomes and that the definition of 
acute kidney injury post TAVI has been much disputed.[29,30] 
Overall, the risk profile of the current cohort of TAVI pa-
tients is consistent with most of other registries’ baseline 
characteristics.[8–10] 
Interestingly, the study showed that there were no statis-
tically significant gender differences in the rate of vascular 
and bleeding complications during the TAVI procedure, 
although many of the previous studies reported more access- 
related vascular and bleeding complications in women.[31–33] 
This may reflect insufficient statistical power, because of 
the small event numbers off these complications in our study 
population (4.2% and 2.4%, respectively), but also may re-
flect the experience of the center and the successful imple-
mentation of vascular closure devices to achieve hemostasis 
post TAVI. 
4.1  Limitations 
The current study is limited by being a retrospective 
analysis, albeit from a prospectively acquired data set. 
However, the principle comparison is being made between 
genders (which are fixed) and thus there is less risk of erro-
neous conclusions from allocation bias. Also, despite that a 
great care was taken in selecting patients, the possibility of 
selection bias reflected by Sex-differences in baseline char-
acteristics and comorbidities cannot be completely ruled out, 
as Men at baseline outnumbered females in term of diabetes 
mellitus, CAD, COPD, dialysis, lower LVEF, higher logis-
Yousif N, et al. Impact of gender on outcomes after TAVI 399 
  
http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology  
tic EuroSCORE while females were older with higher per-
centage of Arterial HTN diagnosis, but it is always infeasi-
ble to balance and standardize the pre-procedural character-
istics giving the fact that TAVI is reserved for elderly pa-
tients with severe AS, deemed high risk for conventional 
surgical intervention and this category of elderly patients 
likely to present with numerous comorbidities. 
4.2  Conclusion 
Female gender is associated with a better survival at 
one-year follow up after TAVI. This finding reflects that 
gender plays a significant prognostic role and should be 
integrated in a potential risk stratification model of patients 
considered for the procedure. On the other hand, risk factors 
could be rendered obsolete, as they do not fit the risk profile 
of a gender based risk assessment. Furthermore, our find-
ings could open the door for a gender tailored medical ther-
apy where males with severe aortic stenosis could benefit 
from a more intense pre-procedural treatment reflected as an 
improvement in survival post valve implantation. 
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